Trial Profile
A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs Fosgonimeton (Primary)
- Indications Alzheimer's disease; Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Athira Pharma
- 24 Mar 2022 According to an Athira Pharma media release, results from this study were published in Journal of Alzheimers Disease.
- 22 Feb 2022 According to an Athira Pharma media release, results from this study will be published in The Journal of Alzheimer's Disease.
- 22 Feb 2022 Results published in the Media Release